Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Eli Lilly will release its third-quarter results this Wednesday. Investors are keen to see how the company has performed, ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

And Eli Lilly's cloud also has a pair of silver linings that investors ... tirzepatide -- a therapy for type 2 diabetes and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also used for weight loss, told CBS News: "Lilly has taken steps to help inform people about the ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...